Zhejiang Medicine announced plans to repurchase shares through centralized bidding. The total buyback amount will be no less than 100 million yuan and no more than 200 million yuan, with a maximum price of 17.9 yuan per share. The estimated number of shares to be repurchased ranges from 5.59 million to 11.17 million, accounting for 0.58% to 1.16% of total share capital. In the first quarter of 2026, the company achieved revenue of 2.191 billion yuan and net profit attributable to the parent company of 287 million yuan.
Zhejiang Medicine Co LtdCompany announces share buyback of 100-200 million yuan, signaling confidence and supporting share price.